sclc232230_S83.txt
— · cohortSC
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSC
- subtype
- cohortSC
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MITOTIC_SPINDLE+0.480
- G2M_CHECKPOINT+0.430
- E2F_TARGETS+0.410
- WNT_BETA_CATENIN_SIGNALING+0.250
- MYC_TARGETS_V1+0.220
- DNA_REPAIR+0.170
- HEDGEHOG_SIGNALING+0.160
- UNFOLDED_PROTEIN_RESPONSE+0.150
- TGF_BETA_SIGNALING+0.140
- PANCREAS_BETA_CELLS+0.110
Top 10 suppressed
- ANGIOGENESIS-0.450
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.430
- INFLAMMATORY_RESPONSE-0.400
- TNFA_SIGNALING_VIA_NFKB-0.390
- ALLOGRAFT_REJECTION-0.350
- COAGULATION-0.350
- INTERFERON_ALPHA_RESPONSE-0.350
- OXIDATIVE_PHOSPHORYLATION-0.350
- XENOBIOTIC_METABOLISM-0.330
- INTERFERON_GAMMA_RESPONSE-0.320
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | msclc591T1_S51.txt | — | cohortSC | 0.925 |
| 2 | SRR22247243 | — | cohortSC | 0.902 |
| 3 | BS_5P1TN10Z | Embryonal tumors | — | 0.895 |
| 4 | SJEPD031372_D1.RNA-Seq | EPN | Supratentorial EPN | 0.895 |
| 5 | TCGA-34-5927-01A-11R-1820-07 | — | cohortSQ1 | 0.894 |
| 6 | SJEPD031150_D1.RNA-Seq | EPN | EPN Tumor | 0.891 |
| 7 | SRR1456903 | GTEX | — | 0.889 |
| 8 | SRR650141 | — | — | 0.885 |
| 9 | BS_7C40TRCY | medulloblastoma | — | 0.883 |
| 10 | BS_NKRYMHEP | medulloblastoma | — | 0.883 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MITOTIC_SPINDLE | 0.480 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.430 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.410 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.250 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.220 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.170 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.160 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.150 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.140 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.110 | Cobimetinib | — uncovered |
| PROTEIN_SECRETION | 0.110 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.100 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.090 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.070 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.030 | Temsirolimus | — uncovered |